Literature DB >> 7582060

Does antihypertensive treatment of the elderly prevent cardiovascular events or prolong life? A meta-analysis of hypertension treatment trials.

K A Pearce1, C D Furberg, J Rushing.   

Abstract

OBJECTIVE: To estimate the short-term effects of drug treatment of hypertension in the elderly (> or = 60 years of age) on stroke, major coronary events, and mortality rates.
DESIGN: Meta-analysis of all published randomized, controlled trials that addressed the impact of drug treatment of hypertension in the elderly on the above outcomes. SETTING AND PATIENTS: All published clinical trials that met the above criteria involved men and women recruited from primary care practices or through community screenings, who were then treated according to protocol at either community or specialty clinics. Eight randomized, controlled trials that included 15,990 patients treated for an average of 4.6 years were included in this meta-analysis.
INTERVENTIONS: Patients received either active antihypertensive treatment or placebo in seven of the studies and programmed stepped care vs referral back to the usual care source in one study. MAIN OUTCOME MEASURES: Fatal or nonfatal myocardial infarction or sudden coronary death; fatal or nonfatal stroke; and all-cause mortality. Outcomes were analyzed on an intention-to-treat basis.
RESULTS: Mean baseline blood pressure was 179/90 mm Hg, with a mean treatment effect of 15/6 mm Hg. Homogeneity tests indicated validity of the combined results. Pooled relative risks, calculated as treatment or control (with 95% confidence intervals) for the main end points, were as follows: fatal or nonfatal major coronary event, 0.82 (0.73 to 0.92); fatal or nonfatal stroke, 0.65 (0.57 to 0.75); and death from any cause, 0.85 (0.78 to 0.92) (P < .005 for each).
CONCLUSION: Antihypertensive treatment in the elderly prevents major coronary events and stroke and prolongs life, with significant treatment effects observed within only 5 years.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7582060     DOI: 10.1001/archfami.4.11.943

Source DB:  PubMed          Journal:  Arch Fam Med        ISSN: 1063-3987


  11 in total

1.  Treating hypertension: the evidence from clinical trials.

Authors:  J A Simon
Journal:  BMJ       Date:  1996-08-24

Review 2.  Drug selection for optimal treatment of hypertension in the elderly.

Authors:  E Shammas; K Dickstein
Journal:  Drugs Aging       Date:  1997-07       Impact factor: 3.923

3.  Addressing barriers to change: an RCT of practice-based education to improve the management of hypertension in the elderly.

Authors:  M Cranney; S Barton; T Walley
Journal:  Br J Gen Pract       Date:  1999-07       Impact factor: 5.386

Review 4.  Losartan: a review of its use, with special focus on elderly patients.

Authors:  K L Simpson; K J McClellan
Journal:  Drugs Aging       Date:  2000-03       Impact factor: 3.923

Review 5.  Pharmacotherapy for hypertension in adults aged 18 to 59 years.

Authors:  Vijaya M Musini; Francois Gueyffier; Lorri Puil; Douglas M Salzwedel; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2017-08-16

6.  Optimal blood pressure on antihypertensive medication.

Authors:  J M Flack
Journal:  Curr Hypertens Rep       Date:  1999-10       Impact factor: 5.369

7.  Cost-effectiveness of implementing new guidelines for treatment of hypertension in general practice.

Authors:  Gerald Richardson; Lesley Godfrey; Hugh Gravelle; Ian Watt
Journal:  Br J Gen Pract       Date:  2004-10       Impact factor: 5.386

8.  Pharmacotherapy for hypertension in adults 60 years or older.

Authors:  Vijaya M Musini; Aaron M Tejani; Ken Bassett; Lorri Puil; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2019-06-05

Review 9.  First-line drugs for hypertension.

Authors:  James M Wright; Vijaya M Musini; Rupam Gill
Journal:  Cochrane Database Syst Rev       Date:  2018-04-18

10.  Methods underpinning national clinical guidelines for hypertension: describing the evidence shortfall.

Authors:  Fiona Campbell; Heather O Dickinson; Julia V F Cook; Fiona R Beyer; Martin Eccles; James M Mason
Journal:  BMC Health Serv Res       Date:  2006-04-05       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.